Generally, therapeutic antibodies are mostly used to target specific proteins on the surface of cells [17], while the key pathogenic BCR/ABL protein of CML is located inside the cells, which limits the use of antibodies for CML target treatment. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.